Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...